Comparative Pharmacology
Head-to-head clinical analysis: BICILLIN versus PENICILLIN V POTASSIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BICILLIN versus PENICILLIN V POTASSIUM.
BICILLIN vs PENICILLIN V POTASSIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzathine penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and autolysin inhibition, leading to cell lysis.
Penicillin V is a bactericidal antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and activating autolytic enzymes.
Benzathine penicillin G 1.2 million units intramuscularly once for early syphilis; 2.4 million units intramuscularly weekly for 3 weeks for late latent syphilis.
250-500 mg orally every 6-8 hours.
None Documented
None Documented
Terminal elimination half-life: 0.5–1 hour (prolonged in renal impairment); clinical context: requires probenecid for extended action
0.5-1 hour in patients with normal renal function; prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min). Clinical context: requires frequent dosing due to short half-life.
Primarily renal (60–70% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%)
Renal excretion of unchanged drug accounts for 20-40% of the dose via glomerular filtration and tubular secretion; biliary excretion is minor (<1%). Fecal elimination is negligible.
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic